The federal response to the coronavirus pandemic has put a Richmond, VA, start-up called Phlow Corp. in the role of preventing shortages of essential medicines and shielding the US market from global competition, particularly from China.
The decision the Health and Human Services Department announced 19 May to provide Phlow with $354m of COVID-19 response funding over the next four years, and possibly another $458m later, could significantly expand the pharmaceutical industry’s boutique federal sector, as protecting the domestic pharmaceutical market from foreign
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?